ClinicalTrials.gg
Not yet recruitingNCT03645486Updated Nov 2, 2026

Lentiviral Gene Therapy for CGD

An interventional study of Infusion of lentiviral TYF-CGD-modified autologous stem cells in Chronic Granulomatous Disease, sponsored by Shenzhen Geno-Immune Medical Institute. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Shenzhen Geno-Immune Medical Institute · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
All
01

Study summary

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

Read the detailed description

Important Regulatory Notice:

This trial record is only for global academic information registration on ClinicalTrials.gov. Neither the sponsor Beijing Meikang Jimian Biotechnology Co., Ltd. nor collaborator Shenzhen Geno-Immune Medical Institute has obtained NMPA clinical trial approval or clinical technology filing permission to carry out interventional cell therapy trials in mainland China.

ClinicalTrials.gov registration alone does not represent legal approval by Chinese health and drug regulatory authorities.

Chronic granulomatous disease (CGD) is a rare disorder caused by inherited defects in the NADPH oxidase multienzyme complex. It is associated with severe and life-threatening bacterial and fungal infections. Approximately two-thirds of all CGD cases result from mutations within the X-linked gp91phox gene (CYBB), followed by the autosomal recessive forms of CGD, with defects in the gene coding for p47phox (NCF1) accounting for 10-30% of all CGD cases.

The primary objectives are to evaluate the safety of the advanced self-inactivating lentiviral vector TYF-CYBB and TYF-NCF1, the ex-vivo gene transfer clinical protocol and the efficacy of immune reconstitution in patients overcoming frequent infections present at the time of treatment, assessment of vector integration sites, and finally the long-term correction of immune dysfunctions.

02

Conditions studied

  • Chronic Granulomatous Disease

Keywords

  • Chronic granulomatous disease
  • Lentiviral vector
03

In context

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

This study's planned enrollment of 10 is below the median of 12 across 57 interventional studies indexed under Granulomatous Disease, Chronic.

Browse Granulomatous Disease, Chronic studies →

Lead sponsor

Shenzhen Geno-Immune Medical Institute is the lead sponsor of 70 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CGD patients >= 0 years of age
  2. Molecular diagnosis confirmed by DNA sequencing and supported by laboratory evidence for absent or significantly reduced biochemical activities of the NADPH-oxidase
  3. -Index > =70%
  4. At least one prior, ongoing or severe infection and/or inflammatory complications requiring hospitalization despite drug intervention
  5. Written for adult patient, and assent for pediatric subjects seven years or older

Exclusion criteria

Exclusion Criteria:

  1. for leukapheresis (anaemia \<8g/dl, cardiovascular instability, severe coagulopathy) or for administration of conditioning medication
  2. Female patients who are pregnant or lactating as determined by history and/or positive pregnancy test
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Lentiviral TYF-CGD-modified autologous stem cells

    Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene

    Genetic: Infusion of lentiviral TYF-CGD-modified autologous stem cells

Interventions

  • GeneticInfusion of lentiviral TYF-CGD-modified autologous stem cells

    Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight

06

What researchers measure

Primary outcomes

  1. Overall survival

    Patient will be monitored for overall health condition, including immune cell assessments, blood biochemistry and metabolitic activities, metabolic detoxification.

    Time frame: 15 year follow up

  2. Gene marking in bone marrow cells

    Gene-modified cells in the bone marrow will be measured by vector-specific quantitative PCR of colony-forming cells. Patient overall survival will be followed up for 15 years.

    Time frame: 15 year follow up

Secondary outcomes

  1. Change in infection frequency

    Time frame: 1 year after treatment by clinical history, complete physical examination, haematological and microbiological tests

  2. Recovery of immune function

    Whole blood cell counts (WBC), including CD3+ CD4, CD8 T cells, CD19+ B cells and CD16/CD56 NK cells, and absolute neutrophil counts (ANC), the percentage of NADPH oxidase positive cells, and the kinetics of transduced cells as determined by dihydrorhodamine (DHR) assay, will be measured.

    Time frame: 1 year follow up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Jun 2028, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2018
First posted
Aug 24, 2018
StartEst.
Jul 1, 2027
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Contact Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03645486
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
Jul 1, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Lung-Ji Chang, Ph.D
Contact
c@mkgimi.com
+86 0755-86573763

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion